Best Oncology Companies in New South Wales, Australia
The 31 best Oncology companies in New South Wales, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kazia Therapeutics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in New South Wales
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Kazia Therapeutics Developer of small molecules for the treatment of cancer | $86M | 11 mo ago | Public | 9 | — | 3 patents Synthesis and application of functionalized benzopyran heterocycles for pharmaceutical use | — |
| 2 | Viralytics Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer. | $83M | 106 mo ago | Acquired | 6 | — | 59 patents Oncolytic virus-based combination immunotherapies for cancer treatment | — |
| 3 | Pharmaxis Developer of drugs for inflammatory and fibrotic diseases | $68M | 51 mo ago | Public | 93 | Gary Phillips CEO | 145 patents Lysyl oxidase inhibitor chemistry and pharmaceutical formulations for fibrosis and oncology | — |
| 4 | Immutep Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $66M | 64 mo ago | Acquired | 35 | Marc Voigt CEO | — | — |
| 5 | ImmVirX Developer of immunotherapy for cancer treatment | $47M | 41 mo ago | Series B | 16 | Malcolm McColl Co-Founder & CEO | — | — |
| 6 | Clinical Genomics Biomarker-based blood tests for early cancer detection | $41M | 101 mo ago | Deadpooled | 50 | Susanne Pedersen Co-Founder & CSO | 256 patents Colorectal cancer epigenetic methylation diagnostics and biomarker panels | — |
| 7 | Clarity Pharmaceuticals Developer of drugs to treat cancer | $28M | 15 mo ago | Public | 41 | — | 129 patents Radiolabeled peptide conjugates for cancer imaging and therapy, especially prostate and neuroendocrine | — |
| 8 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 17 mo ago | Public | 2 | Daniel Kenny Chief Executive Officer | 7 patents Localized radionuclide and drug‑eluting silicon implants for targeted cancer therapy | — |
| 9 | EnGeneIC Developer of targeted anti-cancer therapies using nanocell platform technology | $25M | 115 mo ago | Series B | 30 | — | — | — |
| 10 | Minomic Non-invasive blood tests for cancer | $8M | 119 mo ago | Series A | 14 | Brad Walsh Founder & CEO | — | — |
| 11 | Haemalogix Developer of immunotherapies for blood cancers and autoimmune diseases | $7M | 62 mo ago | Series A | 8 | — | 23 patents Antibody therapeutics and dosing regimens targeting myeloma antigens (LMA/KMA) | — |
| 12 | TruScreen Cervical cancer screening device | $4M | 115 mo ago | Public | — | — | — | — |
| 13 | Beroni Group Developer of cell therapies for treating cancer | $2M | 37 mo ago | Public | 65 | Jacky Zhang CEO | — | — |
| 14 | Immune System Therapeutics Monoclonal antibodies (MAbs) to treat cancers and autoimmune diseases | $700K | 260 mo ago | Deadpooled | — | Rosanne Dunn Co-Founder | 18 patents Therapeutic antibodies and biologics for treating B‑cell mediated immune disorders | — |
| 15 | Respiratory Innovations Medical procedures for monitoring breathing functions and guidance | $400K | 120 mo ago | Deadpooled | — | Sean Pollock COO & Co-Founder | — | — |
Top 12 Oncology companies in New South Wales
#1
Public · Sydney, New South Wales · founded 1994 · 9 employees$85.7Mraised▾
Developer of small molecules for the treatment of cancer. The lead product Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway which regulates growth and cell division is used for the treatment of glioblastoma, DIPG, CNS lymphoma, and brain metastases. Another drug VT801 is a small molecule inhibitor of VEGFR3, which helps in the development of new blood vessels and lymphatic vessels in a growing tumour.
- Dec 2025Post IPO$55.3M
- Aug 2025Post IPO$2.1M
- Jan 2023Post IPO$3.1M
- Oct 2020Post IPO$11.8M
#2
Public · Sydney, New South Wales · founded 2010 · 41 employees$28.1Mraised▾
Developer of drugs to treat cancer. The company utilizes radiopharmaceutical technology for developing targeted therapies. The company has developed drug candidates used for the neuroendocrine tumour, neuroblastoma, colorectal, glioma, and prostate diseases. The company has also developed programs for companion diagnostics in the preclinical stage.
- Jul 2025Post IPO$133.3M
- Mar 2024Post IPO$79M
- Dec 2020Series B$25M
- Jun 2016Grant (prize money)$2.5M
#3
Public · Sydney, New South Wales · founded 2005 · 2 employees$27.8Mraised▾
Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.
- May 2025Post IPO$8.7M
- Apr 2022Post IPO$10M
- Feb 2016Post IPO$7.1M
- 2005Post IPO$2M
#4
Public · Sydney, New South Wales · founded 1998 · 93 employees$68.2Mraised▾
Developer of drugs for inflammatory and fibrotic diseases. The product pipeline has mechanism-based inhibitors of amine oxidases which include Pan-LOX and PXS-5505 for Myelofibrosis, Liver, and pancreatic cancer. It also offers LOXL-2 and PXS-5382 for antifibrotic CKD / IPF / NASH, Pan-LOXand PXS-6302 for anti-scarring, PXS-4699 for anti-inflammatory muscular dystrophy, and PXS-5370 for anti-inflammatory multiple indications.
- Aug 2022Post IPO$5M
- Apr 2021Post IPO$3.4M
- Sep 2020Grant (prize money)$733.8K
- Aug 2018Post IPO$17.7M
#5
Series B · New Lambton, New South Wales · founded 2019 · 16 employees$47Mraised▾
Developer of immunotherapy for cancer treatment. It offers immuno-oncology agents based on oncolytic viruses that infect and kill cancer cells and induce systemic anti-tumor immune responses.
- Jun 2023Series B$25M
- May 2021Series B$22M
#6
Acquired · Sydney, New South Wales · founded 2001 · 35 employees$65.8Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's product line include Eftilagimod alpha for metastatic cancers, IMP761, a humanized IgG4 monoclonal antibody for immunological diseases, and LAG525 for autoimmune diseases.
- Jun 2021Post IPO$44.9M
- Aug 2020Grant (prize money)—
- Sep 2019Post IPO$5M
- Jul 2019Post IPO$520.7K
#7
Acquired · Sydney, New South Wales · founded 2006 · 6 employees$82.7Mraised▾
Viralytics, acquired by Merck in February 2018, is focused on developing oncolytic virotherapy for the treatment of a wide range of cancers. Its lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus (RNA virus) Type A21 (CVA21). It is being evaluated in patients with Melanoma (Phase 2/3); Non-muscle invasive bladder cancer (Phase 1) and one combination study with Keytruda. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells. Their lead candidate in combination with Keytruda had shown positive Phase 1b trial results in patients with late-stage melanoma.
- Jan 2018Post IPO$23.3M
- Jan 2016Post IPO$4M
- Dec 2015Post IPO$28.4M
- Jan 2014Post IPO$27M
#8
Deadpooled · Sydney, New South Wales · founded 2006 · 50 employees$41Mraised▾
Biomarker-based blood tests for early cancer detection. The company's products include Insure ONE which is an in-home collection test for blood in the stool, and COLVERA detects two methylated (silenced) genes, BCAT1 and IKZF1, associated with colorectal tumor growth in circulating tumor DNA.
- Jun 2018Series B$26M
- Mar 2016Series A$15M
#9
Series B · Lane Cove, New South Wales · founded 2000 · 30 employees$25.1Mraised▾
Developer of targeted anti-cancer therapies using nanocell platform technology. The company focuses on research, development, and manufacturing. It utilizes a proprietary nanocell platform for targeted delivery of chemotherapeutics and functional nucleic acids. The technology aims to target tumors directly and leverage the patient’s own immune system.
- Apr 2017Series B$150K
- Jul 2015Series B$2.9M
- Dec 2014Series B$10M
- Aug 2014Series A$7M
#10
Public · Sydney, New South Wales · founded 2014 · 65 employees$2.2Mraised▾
Beroni Group is developing cell therapies for treating cancer. They are developing CAR-T treatment and dendritic cell vaccine therapy. Their lead candidate, PENAO (tumor metabolism inhibitors), is in phase I clinical trials. It targets the adenine nucleotide translocase (ANT) of the inner mitochondrial membrane.
- Sep 2023Post IPO$205.7K
- May 2021Post IPO$2M
#11
Series A · Sydney, New South Wales · founded 2014 · 8 employees$7.5Mraised▾
Developer of immunotherapies for blood cancers and autoimmune diseases. The company offers monoclonal antibodies and CAR T therapeutics for the treatment of multiple myeloma and systemic amyloidosis.
- Sep 2021Series A$7.5M
#12
Series A · Sydney, New South Wales · founded 2000 · 14 employees$8.1Mraised▾
Minomic develops non-invasive blood tests for cancer. Its flagship product MiCheck uses a monclonal antibody to enable detection of a specific cancer-associated protein called Glypican-1. The company claims that the test is more sensitive and accurate than the gold standard prostate-specific antigen tests.
- Dec 2016Series A$3.1M
- Apr 2016Grant (prize money)$572.4K
- Jul 2015Grant (prize money)$360K
- Mar 2012Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Australia
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,017 Australia-affiliated papers.
- University College London121
- Ludwig Cancer Research115
- The University of Queensland85
- Peter MacCallum Cancer Centre73
- Monash University70
- Tumor microenvironment14→125
- Immunotherapy2→101
- Cancer research12→98
- Immune system8→91
- Cancer immunotherapy1→73
- Tumor microenvironment15→206
- Immune system11→145
- Immunotherapy11→133
- Cancer research19→104
- Cancer immunotherapy5→60
- Immunotherapy8→74
- Tumor microenvironment4→57
- Immune system7→53
- Cancer immunotherapy5→30
- Cancer research4→25
Where oncology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.